Browse by author
Lookup NU author(s): Bhavan Rai
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2026 European Association of Urology. Background and objective: This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC, with a focus on clinical presentation. Methods: For the 2026 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included MEDLINE, EMBASE, and the Cochrane Library. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key findings and limitations: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients’ risk stratification and treating them appropriately. Key updates in the 2026 NMIBC Guidelines summary include: the addition of two new tables addressing risk factors for bladder cancer and prognostic factors for progression in subtypes; the addition of two new tables summarising the treatment options for Bacillus Calmette–Guérin (BCG)-unresponsive tumours; inclusion of a new section addressing the addition of immune checkpoint inhibitors to BCG in selected high- and very high-risk NMIBC BCG-NAÏVE patients; a new table addressing the role of urinary markers in follow-up; and the addition of a new section on pragmatic de-intensification strategy for NMIBC. Conclusions and clinical implications: This overview of the 2026 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. They are designed for effective integration into clinical practice. Patient summary The EAU has issued updated clinical practice guidelines on NMIBC. The guidelines provide recommendations for diagnosis, treatment, and follow-up, with a particular focus on quality of life for patients.
Author(s): Gontero P, Mariappan P, Pradere B, Rai BP, Liedberg F, Comperat E, Teoh JY-C, Moschini M, Soria F, van Rhijn BWG, Baard J, Birtle A, Botha M, Capoun O, D'Andrea D, Fiorini E, Masson-Lecomte A, Seisen T, Shariat SF, Smith EJ, Soukup V, Wood R, Xylinas EN, Dominguez-Escrig JL
Publication type: Article
Publication status: Published
Journal: European Urology
Year: 2026
Pages: epub ahead of print
Online publication date: 15/07/2026
Acceptance date: 07/04/2026
ISSN (print): 0302-2838
ISSN (electronic): 1873-7560
Publisher: Elsevier BV
URL: https://doi.org/10.1016/j.eururo.2026.04.009
DOI: 10.1016/j.eururo.2026.04.009
Altmetrics provided by Altmetric
